Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03411031
Title Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

multiple myeloma

Therapies

Elotuzumab + Lenalidomide

Dexamethasone

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.